Line‑of‑business exceptions — verify benefit‑specific prior authorization

Verify whether this policy applies to the patient’s line of business; the policy may not apply to FEP, Medicare Supplement, Medicare Advantage, Medicaid, and certain self‑insured groups — obtain benefit‑specific prior authorization guidance when appropriate.

• Confirm member eligibility and the member‑specific benefit plan prior to requesting authorization.
• If a member‑specific plan differs from the standard benefit plan, the member plan supersedes the policy.

Confirm clinical eligibility and anatomy prior to procedure

Before procedure, document that the patient meets clinical and anatomic eligibility aligned with trial/intended‑use criteria: IPSS ≥13, candidate for a minimally invasive surgical intervention, prostate volume and prostatic urethral length within device‑specified ranges, and absence of key exclusion features (e.g., excessive intravesical prostatic protrusion or obstructive median lobe beyond device allowances).

• Record IPSS score (≥13) and that patient has moderate‑to‑severe LUTS.
• Document prostate volume and prostatic urethral length meet device specifications.
• Note presence or absence of obstructive median lobe and other exclusionary anatomy.

Prior authorization: long‑term evidence and monitoring

When requesting prior authorization, verify whether the patient is enrolled in or will be followed in the FDA‑required post‑approval study and provide rationale for expected long‑term monitoring because available controlled follow‑up is limited to 12 months while FDA requires 60‑month post‑approval studies.

• Include documentation of plans for long‑term follow‑up or post‑approval study participation.
• Acknowledge limited controlled follow‑up in supporting evidence (12 months) and reference FDA 60‑month requirement.

Prior authorization and investigational status — anticipate additional review/denial

Expect investigational denials or additional review during prior authorization and claims adjudication because permanently implanted prostatic stent procedures are designated investigational in this policy.

• Prior authorization is likely required and coverage is unlikely under standard medical‑necessity rules.
• Prepare for potential claim denials for investigational services.

Therapy pathway — consider surgical/ablative options after medical therapy

Consider surgical or ablative therapies (e.g., TURP, MISTs) for patients who have inadequate response to or intolerance of medical therapy; permanently implanted stents are positioned in the therapy pathway after conservative/pharmacologic measures have been considered.

• Reference TURP as the general reference standard for BPH procedural comparisons.
• Minimally invasive surgical treatments (PUL, WVTT, TIPD, aquablation) are alternatives considered before permanent implant in typical pathways.

Document prior conservative/pharmacologic therapy or contraindication

Document that conservative management and guideline‑recommended pharmacotherapy were tried, not tolerated, contraindicated, or refused before considering permanent implant; include specifics of medications attempted or reasons for not using them.

• List prior medications (e.g., alpha‑blockers, 5α‑reductase inhibitors, combination therapy) and duration/response.
• If pharmacotherapy was declined or contraindicated, document the clinical rationale.

Step therapy: document prior alternatives or contraindications

When submitting an authorization or coverage request, include documentation of prior alternatives tried or contraindications to them (e.g., TURP or PUL) because no direct comparative studies exist; absence of documented prior alternatives may affect coverage consideration.

• If TURP or PUL were not attempted, state clinical reasons or documented contraindications.
• Note that no head‑to‑head trials against TURP or PUL are available in the evidence base.

Step therapy — no formal rules; reference professional guidelines

There are no formal step‑therapy rules specified in this policy; follow professional guidelines (AUA, NICE where applicable) and device labeling when considering sequencing of therapies and document adherence to those recommendations.

• Reference AUA guidance for when to consider surgical intervention.
• NICE has guidance only for temporary implants (iTind); no NICE guidance for permanent stents exists.

Coding reference — see Codes table for billing details

Refer to the Codes table for billing and coding details; report applicable CPT Category III codes and ICD‑10‑CM diagnosis per coding guidance when applicable.

• See Codes table for CPT Category III 0941T–0943T and ICD‑10‑CM N40.1 (Benign prostatic hyperplasia with lower urinary tract symptoms).

Benefit verification — confirm member eligibility and benefit plan

Verify member eligibility and the applicable member‑specific benefit plan prior to applying this policy; coverage is subject to member plan terms and may differ from the standard policy.

• Obtain eligibility and benefits information and confirm prior authorization requirements for the member’s line of business.

Clinical eligibility and anatomic documentation — capture IPSS, prior therapy, and device‑compatible anatomy

Document clinical eligibility and anatomic details: confirm IPSS ≥13, prior inadequate response or intolerance to medical therapy or documented refusal of medication, and that prostate anatomy is within device criteria (including prostate volume and urethral length; note median lobe status).

• Record IPSS score and history of medical therapy response or intolerance.
• Provide prostate volume and prostatic urethral length measurements and median lobe assessment.

Required clinical baseline documentation — mirror trial eligibility descriptors

Include required baseline clinical documentation that mirrors trial eligibility: age (typically ≥45–50 years), baseline IPSS thresholds (≥13 or >15 in some studies), prostate volume ranges commonly 25–80 cc (often 30–80 cc), Qmax criteria used in trials (e.g., <12 mL/s), and absence of exclusionary conditions.

• Provide age, baseline IPSS, prostate volume, Qmax, and prior surgical history.
• Document exclusionary findings such as PVR >250 mL, prior prostate surgery, or neurogenic bladder if present.

Coding and documentation — CPT Category III 0941T–0943T; ICD‑10‑CM N40.1

Use the specified CPT Category III and ICD‑10‑CM codes when reporting the procedure and diagnosis: 0941T (insertion/expansion of prostatic urethral scaffold), 0942T (removal and replacement), 0943T (removal), and N40.1 for BPH with LUTS.

• Include the appropriate CPT Category III code and ICD‑10‑CM N40.1 on claims when applicable.

Investigational designation — expect denials for investigational use

Be aware that permanently implanted prostatic stent devices are designated investigational in this policy; claims for investigational services are at risk of denial and prior authorization approvals are unlikely under standard medical‑necessity rules.

• Prepare for coverage denial if procedure is submitted as investigational.
• Provide strong supporting documentation only if pursuing an exception or member‑specific coverage.

Trial‑based exclusion criteria — document features that may preclude coverage

Confirm trial‑based exclusion criteria that could affect coverage: obstructive median lobe beyond specified measurements (e.g., >10 mm IPP or ball‑valve on cystoscopy), post‑void residual >250 mL, prior prostate surgery, and neurogenic bladder — these features were excluded from pivotal trials and may trigger denials if present.

• Measure and document intravesical prostatic protrusion (IPP) and PVR.
• Record prior prostate procedures and neurologic bladder conditions.

Denial risk from insufficient long‑term evidence — document evidence limitations and follow‑up plans

Document that the limited long‑term evidence (controlled follow‑up to 12 months) and the FDA requirement for 60‑month post‑approval studies represent primary evidence gaps; lack of durable efficacy and long‑term complication data increases the risk of denial.

• Include acknowledgment of evidence limitations and plans for long‑term follow‑up when seeking prior authorization.
• Highlight absence of long‑term data on encrustation, migration, and tissue reaction.

Investigational stance may trigger denial — ProVee and Zenflow devices

Expect that investigational stance for devices such as ProVee and Zenflow may trigger prior authorization denials or claim rejections; reference the policy designation and include any supporting rationale if seeking an exception.

• Specifically note device identity (e.g., ProVee System, Zenflow Spring Implant) when submitting requests.
• Attach trial or post‑approval study enrollment documentation if available to reduce denial risk.